NCT01589640Unknown不适用
Phase 4 Study Accessing Patient Satisfaction and Tear Osmolarity While Using Blink Tears, Blink Gel Tears and Systane Balance
Ophthalmic Consultants of Connecticut1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2012年5月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Primary efficacy variable is tear osmolarity
研究概览
简要总结
This is a single center clinical study designed to determine patient satisfaction and the effect of the use of artificial tears on tear osmolarity with time after instillation of three commercially available artifical tear eye solutions ( Blink Tears, Blink Gel Tears and Systane Balance).
详细描述
Patient satisfaction and tear osmolarity with the use of Blink Tears, Blink Gel Tears and Systane Balance.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •male or femal subjects (aged 18 or older)
- •diagnosed with mild to moderate dry eye syndrome
- •provide written informed consent and sign/date a health information release
- •women of childbreaing potential must be willing to practice effective contraception for the duration of the study.
排除标准
- •have any active ocular disease other than mild to moderate dry eye sundrome that would interfere with study interpretation
- •active ocular allergy in any eye
- •history of or active ocular infection/inflammation
- •concomitant use of contact lenses (unilateral or bilateral)
- •history of any corneal refractive laser surgery (e.g., LASIK, LASEK, RK,PRK) in the study eye (s);
- •corneal disorder or abnormality that affects cornea sensitivity or normal spreading of the tear film in any eye.
- •history of any intaocular surgery or glaucoma laser surgery (e.g., ALT, SLT) in the study eye (s)
- •known sensitivity or allergy to any of the study medications or their components;
- •uncontrolled systemic disease;
- •contraindication to pupil dilation;
- •Schirmer's Test- Standard Test (with anesthesia) result of less than or equal to 3 MM
- •use of artifical tears prior to Baseline Visit (Visit 2, Day 0);
- •Current use, use within 2 weeks prior to Baseline Visit ( Visit 2,Day 0) or likely use during the study period of any topical ophthalmic medications (e.g., antibotics, glaucoma medications) other than ophthalmic medications used in the study.
- •use of any omega 3 supplement, artificial tear product (s), vasoconstrictor and/or redness reliever ocular drops 30 days prior to or during the study perior;
- •use of cyclosporine ocular drops 12 months prior to or will require ocular surgery during the study period.
- •females who are pregnany, nursing or planning a pregnancy or who are of childbearing potenital and not using a reliable method of contraception;
- •any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and
- •concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Screening Visit (Visit 1)
结局指标
主要结局
Primary efficacy variable is tear osmolarity
时间窗: 28 days
次要结局
- Secondary efficacy variable is the Patient Symptom Questionnaire(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Vivity Insight: A Study of Patient Satisfaction and Visual PerformanceCataractNCT04495049Research Insight LLC60
已完成
不适用
Patient Satisfaction in Cutaneous SurgerySkin CancerNCT01535963Northwestern University354
招募中
不适用
Patient Satisfaction and Crestal Bone Changes Around One-piece Zirconia(Zr) and Titanium(Ti) in Implant-Retained Mandibular OverdentureComplete EdentulismNCT06643975Ain Shams University20
尚未招募
Unknown
A Study for satisfaction related to artificial limb in lower limb amputeesCTRI/2024/02/062353PGIMER post graduate institute of medical education and research Chandigarh
已完成
不适用
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of LifePsoriasis VulgarisNCT01982552LEO Pharma147